Literature DB >> 21883145

Ketamine-induced ventricular structural, sympathetic and electrophysiological remodelling: pathological consequences and protective effects of metoprolol.

Y Li1, J Shi1, B F Yang1, L Liu1, C L Han1, W M Li1, D L Dong1, Z W Pan1, G Z Liu1, J Q Geng1, L Sheng1, X Y Tan1, D H Sun1, Z H Gong1, Y T Gong1.   

Abstract

BACKGROUND AND
PURPOSE: Growing evidence suggests that long-term abuse of ketamine does harm the heart and increases the risk of sudden death. The present study was performed to explore the cardiotoxicity of ketamine and the protective effects of metoprolol. EXPERIMENTAL APPROACH: Rats and rabbits were divided into control, ketamine, metoprolol alone and ketamine plus metoprolol groups. Ketamine (40 mg·kg(-1) ·day(-1), i.p.) and metoprolol (20 mg·kg(-1) ·day(-1), p.o.) were administered continuously for 12 weeks in rats and 8 weeks in rabbits. Cardiac function, electrophysiological disturbances, cardiac collagen, cardiomyocte apoptosis and the remodelling-related proteins were evaluated. KEY
RESULTS: Rabbits treated with ketamine showed decreased left ventricular ejection fraction, slowed ventricular conduction velocity and increased susceptibility to ventricular arrhythmia. Metoprolol prevented these pathophysiological alterations. In ketamine-treated rats, cardiac collagen volume fraction and apoptotic cell number were higher than those of control animals; these effects were prevented by co-administration of metoprolol. Consistently, the expressions of poly (ADP-ribose) polymerases-1, apoptosis-inducing factor and NF-κB-light-chain-enhancer of activated B cells were all increased after ketamine treatment and sharply reduced after metoprolol administration. Moreover, ketamine enhanced sympathetic sprouting, manifested as increased growth-associated protein 43 and tyrosine TH expression. These effects of ketamine were prevented by metoprolol. CONCLUSIONS AND IMPLICATIONS: Chronic treatment with ketamine caused significant ventricular myocardial apoptosis, fibrosis and sympathetic sprouting, which altered the electrophysiological properties of the heart and increased its susceptibility to malignant arrhythmia that may lead to sudden cardiac death. Metoprolol prevented the cardiotoxicity of ketamine, indicating a promising new therapeutic strategy.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21883145      PMCID: PMC3372827          DOI: 10.1111/j.1476-5381.2011.01635.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Guide to Receptors and Channels (GRAC), 5th edition.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

2.  Cardiac remodeling and contractile function in acid alpha-glucosidase knockout mice.

Authors:  J H Kamphoven; R Stubenitsky; A J Reuser; A T Van Der Ploeg; P D Verdouw; D J Duncker
Journal:  Physiol Genomics       Date:  2001-04-27       Impact factor: 3.107

3.  Quantitative comparison of growth-associated protein-43 and substance P in ulcerative colitis.

Authors:  P Vento; T Kiviluoto; U Keränen; H J Järvinen; E Kivilaakso; S Soinila
Journal:  J Histochem Cytochem       Date:  2001-06       Impact factor: 2.479

4.  Nerve sprouting and sudden cardiac death.

Authors:  J M Cao; L S Chen; B H KenKnight; T Ohara; M H Lee; J Tsai; W W Lai; H S Karagueuzian; P L Wolf; M C Fishbein; P S Chen
Journal:  Circ Res       Date:  2000-04-14       Impact factor: 17.367

5.  A fatal ketamine poisoning.

Authors:  M Licata; G Pierini; G Popoli
Journal:  J Forensic Sci       Date:  1994-09       Impact factor: 1.832

6.  Patterns of use and harms associated with non-medical ketamine use.

Authors:  Paul Dillon; Jan Copeland; Karl Jansen
Journal:  Drug Alcohol Depend       Date:  2003-01-24       Impact factor: 4.492

7.  Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias.

Authors:  I T Meredith; A Broughton; G L Jennings; M D Esler
Journal:  N Engl J Med       Date:  1991-08-29       Impact factor: 91.245

8.  Evaluation of detomidine anesthetic combinations in the rabbit.

Authors:  R J Hurley; R P Marini; D L Avison; J C Murphy; J M Olin; N S Lipman
Journal:  Lab Anim Sci       Date:  1994-10

Review 9.  Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.

Authors:  Kelly M Smith; Lisa L Larive; Frank Romanelli
Journal:  Am J Health Syst Pharm       Date:  2002-06-01       Impact factor: 2.637

Review 10.  PARP goes transcription.

Authors:  W Lee Kraus; John T Lis
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

View more
  14 in total

1.  Intact urothelial barrier function in a mouse model of ketamine-induced voiding dysfunction.

Authors:  Retnagowri Rajandram; Teng Aik Ong; Azad H A Razack; Bryce MacIver; Mark Zeidel; Weiqun Yu
Journal:  Am J Physiol Renal Physiol       Date:  2016-02-24

2.  Resveratrol prevents atrial fibrillation by inhibiting atrial structural and metabolic remodeling in collagen-induced arthritis rats.

Authors:  Yun Zhang; Song Zhang; Zonghong Liu; Xinbo Zhao; Yue Yuan; Li Sheng; Yue Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-22       Impact factor: 3.000

3.  Continuous Rate Infusion of Ketamine Hydrochloride and Dexmedetomidine for Maintenance of Anesthesia during Laryngotracheal Surgery in New Zealand White Rabbits (Oryctolagus cuniculus).

Authors:  Lea J Sayce; Maria E Powell; Emily E Kimball; Patty Chen; Gary J Gartling; Bernard Rousseau
Journal:  J Am Assoc Lab Anim Sci       Date:  2020-01-31       Impact factor: 1.232

4.  Role of the β3-adrenergic receptor subtype in catecholamine-induced myocardial remodeling.

Authors:  Gizem Kayki Mutlu; Ebru Arioglu Inan; Irem Karaomerlioglu; V Melih Altan; Nilgun Yersal; Petek Korkusuz; Marcella Rocchetti; Antonio Zaza
Journal:  Mol Cell Biochem       Date:  2018-01-23       Impact factor: 3.396

5.  Mechanistic studies on ketamine-induced mitochondrial toxicity in zebrafish embryos.

Authors:  Bonnie L Robinson; Melanie Dumas; Syed F Ali; Merle G Paule; Qiang Gu; Jyotshna Kanungo
Journal:  Neurotoxicol Teratol       Date:  2017-12-07       Impact factor: 3.763

6.  Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway.

Authors:  Guang-Zhong Liu; Ting-Ting Hou; Yue Yuan; Peng-Zhou Hang; Jing-Jing Zhao; Li Sun; Guan-Qi Zhao; Jing Zhao; Jing-Mei Dong; Xiao-Bing Wang; Hang Shi; Yong-Wu Liu; Jing-Hua Zhou; Zeng-Xiang Dong; Yang Liu; Cheng-Chuang Zhan; Yue Li; Wei-Min Li
Journal:  Br J Pharmacol       Date:  2016-02-18       Impact factor: 8.739

7.  The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms.

Authors:  Khanh Vinh Quốc Lu'o'ng; Lan Thi Hoàng Nguyễn
Journal:  Cancer Manag Res       Date:  2012-12-18       Impact factor: 3.989

8.  Environmental enrichment and abstinence attenuate ketamine-induced cardiac and renal toxicity.

Authors:  Xingxing Li; Shuangyan Li; Wenhui Zheng; Jian Pan; Kunyu Huang; Rong Chen; Tonghe Pan; Guorong Liao; Zhongming Chen; Dongsheng Zhou; Wenwen Shen; Wenhua Zhou; Yu Liu
Journal:  Sci Rep       Date:  2015-06-26       Impact factor: 4.379

9.  Chronic obstructive sleep apnea promotes aortic remodeling in canines through miR-145/Smad3 signaling pathway.

Authors:  Chengyuan Yu; Yang Liu; Li Sun; Dingyu Wang; Yike Wang; Shiqi Zhao; Hui Dai; Jing Zhao; Song Zhang; Minghui Li; Yu Han; Shuang Lu; Xinwen Dong; Guangzhong Liu; Shengzhu Yu; Yue Li
Journal:  Oncotarget       Date:  2017-06-06

10.  Ketamine-mediated afferent-specific presynaptic transmission blocks in low-threshold and sex-specific subpopulation of myelinated Ah-type baroreceptor neurons of rats.

Authors:  Lu-Qi Wang; Sheng-Zhi Liu; Xin Wen; Di Wu; Lei Yin; Yao Fan; Ye Wang; Wei-Ran Chen; Pei Chen; Yang Liu; Xiao-Long Lu; Hong-Li Sun; Weinian Shou; Guo-Fen Qiao; Bai-Yan Li
Journal:  Oncotarget       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.